Healthcare Industry News: Ampion
News Release - July 31, 2008
Sweden to Receive Scandinavia's First TomoTherapy SystemLund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TOMO ) announced today that it has extended its reach in Europe with the first TomoTherapy® Hi∙Art® treatment system set to be installed in Scandinavia, at Lund University Hospital in Sweden.
Jef Van Dam, general manager of TomoTherapy EMEA, said, "TomoTherapy is extremely pleased to partner with Lund University Hospital. This marks our entry into the Swedish market with a prestigious institution that pioneered the use of many technological advances in Scandinavia and Europe. We look forward to delivering the advanced Hi∙Art system to continue that tradition."
Lund University Hospital conducted an extensive investigation of all commercially available intensity-modulated radiation therapy (IMRT) systems, including arc-based options on conventional platforms, before making the decision to purchase the TomoTherapy Hi∙Art system.
Charlott Wictor, strategic purchaser of medical equipment for the Skane region in Sweden, chAmpioned TomoTherapy and helped the purchase become reality: “This was a great team effort working with the Lund medical and physics experts to bring this advanced technology to our Swedish patients. TomoTherapy was clearly the best choice from both a high technology and economic standpoint.”
Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund University Hospital, believes TomoTherapy will have a great impact on patient treatments. “As a large center treating 2500 new patients yearly, we are dependent on high up-time and clinical reliability. The established and clinically well-implemented TomoTherapy Hi∙Art was the only system that could meet the demands of our clinic.”
Tommy Knöös, Ph.D., associate professor and head of radiation physics at Lund University Hospital, was also an important decision maker in the process. “We think TomoTherapy is the most advanced image-guided system for radiotherapy with an integrated functionality for imaging and localisation of the target volume. It also produces the most advantageous dose distributions for IMRT,” according to Knöös.
Added Engellau, “With the Hi∙Art system, we see obvious clinical advantages for treating complex radiation target volumes, multiple targets and targets requiring a high radiation dose with close proximity to healthy organs. Conventional 3D conformal radiation or IMRT can treat some but not all of these case types. If the cases can be attempted, we believe the results would be less conformal, less accurate and with much longer treatment times than with TomoTherapy.”
While TomoTherapy will be used to treat a wide array of cancers, the clinical experts at Lund plan to focus on anal, rectal, cervical, stomach and esophageal cancers. They will also be using the Hi∙Art system for stereotactic radiosurgery treatments and see greater possibilities for clinical trials involving simultaneously integrated boost (SIB) with or without dose escalation.
Lund University Hospital plans to install the TomoTherapy Hi∙Art system later this year.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Statements in this release regarding future events, expectations and other similar matters, including but not limited to statements using the terms “look forward to” or “will” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.